ornithine has been researched along with sildenafil citrate in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Angelini, GD; Jeremy, JY; Muzaffar, S; Shukla, N; Srivastava, A | 1 |
| Castro, O; Gladwin, MT; Harris, A; Hauser, KP; Kato, G; Little, JA; Machado, R; Maric, I; Martyr, SE; Morris, CR; Suh, JH; Taylor, J | 1 |
2 other study(ies) available for ornithine and sildenafil citrate
| Article | Year |
|---|---|
Sildenafil citrate and sildenafil nitrate (NCX 911) are potent inhibitors of superoxide formation and gp91phox expression in porcine pulmonary artery endothelial cells.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Animals; Cells, Cultured; Cyclic GMP; Endothelial Cells; Guanylate Cyclase; Male; Membrane Glycoproteins; NADPH Oxidases; Nitric Oxide; Nitric Oxide Synthase; Ornithine; Oxadiazoles; Piperazines; Protein Kinase Inhibitors; Pulmonary Artery; Purines; Quinoxalines; Sildenafil Citrate; Sulfones; Superoxides; Swine; Thionucleotides | 2005 |
Hematologic, biochemical, and cardiopulmonary effects of L-arginine supplementation or phosphodiesterase 5 inhibition in patients with sickle cell disease who are on hydroxyurea therapy.
Topics: Adult; Anemia, Sickle Cell; Arginase; Arginine; beta-Globins; Citrulline; Cyclic Nucleotide Phosphodiesterases, Type 5; Female; Fetal Hemoglobin; Humans; Hydroxyurea; Male; Middle Aged; Ornithine; Phosphodiesterase Inhibitors; Piperazines; Purines; Reticulocyte Count; Sildenafil Citrate; Sulfones | 2009 |